Lunit said it signed a supply agreement with Abu Dhabi Health Services Company (SEHA), the largest healthcare provider in the Middle East, to provide Lunit INSIGHT MMG, its AI-powered mammography analysis solution.

With this contract, Lunit will officially commence its participation in the UAE's national breast cancer screening program.

Lunit has been expanding its presence in the global cancer screening market since 2022, starting in Australia and later entering Sweden, Iceland, several Latin American countries, and the Middle East, including Saudi Arabia and Qatar. The latest UAE contract further accelerates Lunit’s expansion into the global B2G (business-to-government) market.

Established in 2007, SEHA is the largest integrated healthcare network in the Middle East, operating 14 general hospitals and 70 clinics, with over 3,000 hospital beds and more than 2,300 physicians.

The agreement follows nearly two years of validation after Lunit and SEHA signed an MOU in October 2022. During this period, local medical institutions tested Lunit’s AI solutions, confirming their effectiveness. As part of the deal, SEHA will utilize Lunit’s AI technology to analyze over 100,000 mammography images over the next five years.

"This agreement is a testament to the UAE medical community’s recognition of the superior performance of Lunit’s AI solutions after a rigorous evaluation process," Lunit CEO Suh Beom-seok said. “With the rapid adoption of AI in the Middle Eastern healthcare sector, we will leverage this milestone to expand our global cancer screening business further."

According to a report by global market research firm Grand View Research, the Middle East’s medical AI market was valued at approximately $200 million by the end of last year.

This figure is expected to surge to $1.5 billion within the next five to seven years. In the UAE, a country known for its advanced medical infrastructure, the AI healthcare market is experiencing an annual growth rate of 34.6 percent, with projections estimating it will reach $137.9 million by 2030.